BSE Live
Sep 05, 16:01Prev. Close
6135.80
Open Price
6106.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 05, 15:58Prev. Close
6133.50
Open Price
6133.50
Bid Price (Qty.)
6009.00 (217)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Divis Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 9,163.00 | 7,616.00 | 7,523.73 | 8,719.22 | 6,687.55 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 9,163.00 | 7,616.00 | 7,523.73 | 8,719.22 | 6,687.55 | |
Total Operating Revenues | 9,198.00 | 7,665.00 | 7,625.30 | 8,879.82 | 6,798.61 | |
Other Income | 352.00 | 337.00 | 349.01 | 111.26 | 62.53 | |
Total Revenue | 9,550.00 | 8,002.00 | 7,974.31 | 8,991.08 | 6,861.14 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 3,760.00 | 3,210.00 | 2,979.49 | 3,439.79 | 2,365.50 | |
Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -83.00 | -127.00 | 50.16 | -449.99 | -100.00 | |
Employee Benefit Expenses | 1,210.00 | 1,067.00 | 953.05 | 926.55 | 808.68 | |
Finance Costs | 1.00 | 3.00 | 0.52 | 0.65 | 0.69 | |
Depreciation And Amortisation Expenses | 401.00 | 376.00 | 342.07 | 310.55 | 254.65 | |
Other Expenses | 1,332.00 | 1,341.00 | 1,294.92 | 1,087.01 | 903.75 | |
Total Expenses | 6,621.00 | 5,870.00 | 5,620.21 | 5,314.56 | 4,233.27 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,929.00 | 2,132.00 | 2,354.10 | 3,676.52 | 2,627.87 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 2,929.00 | 2,132.00 | 2,354.10 | 3,676.52 | 2,627.87 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 793.00 | 511.00 | 437.58 | 637.20 | 609.05 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -73.00 | 45.00 | 108.37 | 90.78 | 64.10 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 720.00 | 556.00 | 545.95 | 727.98 | 673.15 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 2,209.00 | 1,576.00 | 1,808.15 | 2,948.54 | 1,954.72 | |
Profit/Loss From Continuing Operations | 2,209.00 | 1,576.00 | 1,808.15 | 2,948.54 | 1,954.72 | |
Profit/Loss For The Period | 2,209.00 | 1,576.00 | 1,808.15 | 2,948.54 | 1,954.72 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 83.20 | 59.37 | 68.11 | 111.07 | 73.63 | |
Diluted EPS (Rs.) | 83.20 | 59.37 | 68.11 | 111.07 | 73.63 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 796.00 | 796.00 | 796.41 | 530.94 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 1,500.00 | 1,500.00 | 1,500.00 | 1,500.00 | 1,000.00 |
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
21.05.2025
Reduce Divi's Laboratories: target of Rs 5,610: ICICI Securities
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill